Genmab and BliNK Biomedical Enter into Commercial License Agreement

World News: . []

With this agreement the scope of product LINK  under development at Genmab has been expanded CD47 has shown LINK  as a target for cancer and we LINK  that a bispecific approach may open up potential for differentiated therapies We are always ...

More news and information about Genmab A/S

Published By:

Globe Newswire: 11:00 GMT Friday 12th July 2019

Published: .

Search for other references to "genmab" on SPi News


Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2020. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.
Privacy Policy | Terms and Conditions | Contact Us